Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Large Abdominal Wall Lipoma Causes Bowel Obstruction
Proteus syndrome is a complex disorder associated with varied, disproportionate, asymmetric overgrowth of many body parts and unregulated adipose tissue. The overgrowth seen in Proteus syndrome is progressive and difficult to manage. Patients with Proteus syndrome require repeated treatment for the progressive overgrowth of tissue over a long period. Aggressive treatment may cause severe functional and cosmetic consequences, so surgical intervention is often delayed until it is absolutely necessary.
generic viagra online
White House Budget Chief Says Issue Of Abortion Coverage In Health Reform Still Under Debate
In an appearance on "Fox News Sunday," White House Office of Management and Budget Director Peter Orszag said that he is "not prepared to say explicitly" whether health care reform legislation would prohibit the use of federal tax revenue to fund abortion coverage, the New York Times reports. Orszag"s statement came in reply to a question asking whether he was prepared to say that "no taxpayer money will go to pay for abortions." Orszag said, "It"s obviously a controversial issue, and it"s one of the questions that is playing out in the debate" (Pear/Liptak, New York Times, 7/20).Sen. Judd Gregg (R-N.H.), who also appeared on "Fox News Sunday," said, "No matter what your views are on abortion, you shouldn"t ask people to use their tax dollars if they think that abortion is taking a life." Gregg added, "I would hate to see the health care debate go down over that issue. We do really need health care reform, and it has to be substantive. ... So hopefully we won"t get ourselves wrapped around the wheel of abortion in this debate" (FoxNews.com, 7/19). According to the Times, there is an ongoing behind-the-scenes debate over handling abortion coverage in health overhaul legislation. The debate affects both the public insurance plan the legislation would create and private insurers, who would receive tens of billions of dollars in federal subsidies to expand coverage for low- and moderate-income U.S. residents. A provision in the House health reform bill (HR 3200) calls for a federal advisory committee to advise the HHS secretary on an "essential benefits package" that most insurers would be required to provide. Abortion-rights opponents want abortion coverage excluded from the package, while abortion-rights advocates say the decision should be left to medical professionals. House committees working on health reform legislation have rejected Republican amendments that would have restricted abortion coverage. The Hyde Amendment, first enacted in 1976, prohibits the use of federal Medicaid money for abortion services. However, abortion-rights opponents argue that federally subsidized coverage of the uninsured would not be subject to the existing restrictions. The National Right to Life Committee issued an analysis of the House bill, stating, "There is no doubt that coverage of abortion will be mandated, unless Congress explicitly excludes abortion from the scope of federal authority to define "essential benefits."" According to the group, even if the HHS secretary did not require abortion coverage, "federal courts would interpret the broadly worded mandatory categories of coverage to include abortion" (New York Times, 7/20).
News of the day
Abbott And AstraZeneca Submit New Drug Application To The FDA For CERTRIAD™, An Investigational Treatment For Mixed Dyslipidemia
Abbott Park, Illinois (NYSE: ABT) and London, UK - Abbott and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR® (rosuvastatin calcium) and TRILIPIX® (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD™.
Cardiovascular

Mars And Venus: Short- And Long-Term Success Of Male To Female Kidney Transplants

Female recipients of kidneys from deceased male donors demonstrate an increased risk of allograft failure in the first year after transplant, but show no increased risk after ten years, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The study authors note that proteins on male donor cells may affect the short term success of kidney transplants in women. Joseph Kim, MD (Toronto General Hospital and the University of Toronto, Canada) and John Gill, MD (St. Paul"s Hospital and the University of British Columbia, Canada) studied information on all adult recipients of deceased-donor kidney transplants from 1990 through 2004 in the United States Renal Data System (a system that collects, analyzes, and distributes information about end-stage renal disease in the United States). 117,877 patients were followed for at least one year post transplant. Of these, 16,135 experienced kidney graft failure and 6,878 died within the year. 97,906 patients had functioning grafts at 1-year and were followed for up to 10 years post-transplant. Of these, 35,084 graft failures and 22,566 deaths occurred. The results of this analysis indicate that H-Y antigens, derived from the male chromosome and not found in women, may elicit an immune response in women who receive transplants from deceased male donors. Compared with all other sex combinations, female recipients of male donor kidneys had a 12% increased risk for transplant failure at one year but no excess risk at 10 years. Women who received male donor kidneys also exhibited a similar increased risk of death in the first year, but no increased risk at 10 years. Dr. Kim noted that there are numerous factors that contribute to the success of kidney transplants and that transplanting male kidneys into female recipients often produces excellent outcomes. According to the authors, many important factors should be taken into account when considering transplant options, and "future research should examine the potential mechanisms underlying the H-Y effect in order to better understand the specific role of minor histocompatibility antigens in determining kidney allograft outcomes." The American Society of Nephrology (ASN) does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies. Founded in 1966, ASN is the world"s largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians. American Society of Nephrology (ASN)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009